Pancreatic Neoplasms
Conditions
Keywords
Pancreatic neoplasms, Single-cell sequencing, Immune microenvironment
Brief summary
Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.
Interventions
DIAGNOSTIC_TESTSingle-cell Sequencing Analysis
Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.
Sponsors
Fujian Medical University Union Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* 18 years ≤ age ≤ 75 years. * Resectable/borderline resectable pancreatic cancer patients diagnosed based on pathological and preoperative imaging evaluation. * No prior history of any form of anti-tumor treatment. * At least one measurable lesion. * Eastern Cooperative Oncology Group (ECOG): 0-1. * Not participated in any other clinical studies before or during treatment. * Willingness to participate voluntarily in this study, signing an informed consent form.
Exclusion criteria
* History of any other malignant tumor, except for completely resected basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, within the past 5 years. * Vaccination with live vaccines within 4 weeks prior to enrollment or during the study period. * Active autoimmune diseases or a history of autoimmune diseases within the past 4 weeks before enrollment. * Allogeneic bone marrow or organ transplantation. * Active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors in the gastrointestinal tract, or other conditions determined by the investigator that may cause gastrointestinal bleeding or perforation. * Evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding \>30 mL within 3 months, hematemesis, melena, or hematochezia), hemoptysis (\>5 mL of fresh blood within 4 weeks), or occurrence of thromboembolic events within 12 months (including stroke events and/or transient ischemic attacks).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Bioinformatics analysis of single-cell sequencing results | Collected during surgical treatment | Using single-cell sequencing technology, in-depth analysis of surgical samples from resectable/borderline resectable pancreatic cancer patients is conducted to investigate the composition and interactions of the tumor microenvironment in pancreatic cancer. |
Countries
China
Contacts
Primary ContactYu Pan, M.D.
Outcome results
None listed